Undone Science and Blind Spots in Medical Treatment Research: A Case Study

Tom Cleary

Abstract


Age-related Macular Degeneration (AMD) is a serious eye disease. Two similar drugs, Lucentis and Avastin, are available to slow the progression of wet AMD. Research has been carried out on the highly profitable drug Lucentis, so governments have licensed it for use, whereas equivalent research and formal licensing of Avastin for treatment of eye disease has been delayed and discouraged. This is a case illustrating the problem of undone science: research in socially beneficial areas may be neglected for commercial or political reasons.

Key words: Age-related Macular Degeneration; undone science; Lucentis; Avastin; eye disease

Full Text:

PDF

 

Please feel free to comment on this article:

blog comments powered by Disqus


Editorial Offices:

Department of Family and Social Medicine
Albert Einstein College of Medicine/Montefiore Medical Center
Bronx, New York, 10461

Asociación Latinoamericana de Medicina Social (ALAMES)/Latin American Social Medicine Association:
ALAMES, Southern Cone Region, Cassinoni 1440 – 802, CP 11200 Montevideo, Uruguay.
ALAMES, Mexico Region, San Jerónimo 70 – 1, Col. La Otra Banda, CP 01090, México, D.F.